Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 7/2016

01-06-2016 | Letter to the Editor

Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib

Authors: Benoit Branco, David Metsu, Marine Dutertre, Bruno Marchou, Pierre Delobel, Christian Recher, Guillaume Martin-Blondel

Published in: Annals of Hematology | Issue 7/2016

Login to get access

Excerpt

Dear Editor, …
Literature
1.
O’Shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368(2):161–170CrossRefPubMed
2.
von Hofsten J, Johnsson Forsberg M, Zetterberg M (2016) Cytomegalovirus retinitis in a patient who received ruxolitinib. N Engl J Med 374(3):296–297CrossRef
3.
Chen Y-H, Lee C-H, Pei S-N (2015) Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma 56(5):1528–1529CrossRefPubMed
4.
Palandri F, Polverelli N, Catani L, Vianelli N (2014) Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge. Ann Hematol 94(3):519–520CrossRefPubMed
5.
Hopman RK, Lawrence SJ, Oh ST (2014) Disseminated tuberculosis associated with ruxolitinib. Leukemia 28(8):1750–1751CrossRefPubMed
6.
Colomba C, Rubino R, Siracusa L, Lalicata F, Trizzino M, Titone L, Tolomeo M (2012) Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 5:552CrossRefPubMedPubMedCentral
7.
Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, Scherle PA, Punwani NG, Williams WV, Yeleswaram S (2011) The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol 51(12):1644–1654CrossRefPubMed
8.
Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y (2012) The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol 52(6):809–818CrossRefPubMed
Metadata
Title
Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib
Authors
Benoit Branco
David Metsu
Marine Dutertre
Bruno Marchou
Pierre Delobel
Christian Recher
Guillaume Martin-Blondel
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 7/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2684-0

Other articles of this Issue 7/2016

Annals of Hematology 7/2016 Go to the issue

Original Article

High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin’s lymphoma

Original Article

The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT)

Original Article

Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring of myeloma bone disease

Letter to the Editor

Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia

Original Article

Correlation between ‘H’ blood group antigen and Plasmodium falciparum invasion

Letter to the Editor

Amisulpride induced agranulocytosis: a case report
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits